StockNews.AI
MRNA
StockNews.AI
18 days

Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates

1. Moderna reports $0.1 billion Q2 revenue and $(0.8) billion net loss. 2. Projected 2025 revenue reduced to $1.5-$2.2 billion due to delivery timings.

3m saved
Insight
Article

FAQ

Why Bearish?

Despite FDA approvals, revenue cut raises concerns about future sales growth. Historical context shows revenue reductions often lead to stock price declines.

How important is it?

Financial results, revenue adjustments, and FDA approvals hold significant implications for MRNA's financial future.

Why Short Term?

Immediate concerns over Q2 results and revised forecasts will influence investor sentiment. Revenue timing issues typically impact stock prices swiftly.

Related Companies

PFEJNJNVAX
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end, primarily driven by timing of deliveries for contracted revenue into the first quarter of 2026 Improves 2025 expected GAAP operating expenses by approximately $400 million to a range of $5.9 to $6.1 billion Reiterates 2025 expected year-end cash balance of approximately $6 billion Announced three recent U.S. FDA approvals and positive Phase 3 efficacy results for seasonal influenza vaccine CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine efficacy data and expanded our commercial portfolio with three new U.S. FDA approvals to drive future sales growth," said Stéphane Bancel, Chief Executive Officer of Moderna.

Related News